Does it matter whether you use a clinical registry or administrative database to calculate drug persistence rates?

The answer is yes! Colleagues from The Janssen Pharmaceutical Companies of Johnson & JohnsonQuantify Research and our CEO Kirk Geale recently published a literature review in the Journal of Drugs in Dermatology (JDD) examining the systematic differences in biologic drug persistence rates when calculated from administrative claims data vs clinical registry data. This paper helps practitioners interpret and compare the results from studies with different data sources.

Our main finding: Persistence calculated from registries appears systematically higher than those calculated from administrative databases.

Check out the full paper here:

#healthcare #rwe #psoriasis #research #publication